Login Register Cart 0
Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Advancements in Metal Complexation of Pyridine Derivatives (2022–2024): A Pathway to Enhanced Anticancer Potency

Author(s): Nouf A. Babteen*

Volume 25, Issue 20, 2025

Published on: 24 April, 2025

Page: [1571 - 1587] Pages: 17

DOI: 10.2174/0118715206378693250414044912

Price: $65

Abstract

Cancer remains a major global health challenge, necessitating innovative therapies that selectively target cancer cells while sparing healthy tissues. Pyridine and its derivatives have gained prominence in medicinal chemistry for their structural diversity and biological activity. However, their therapeutic potential is often hindered by low bioavailability, poor solubility, and rapid metabolism. Metal complexation has emerged as a promising solution, with pyridine nitrogen serving as an excellent coordination site for transition metals. These pyridinemetal complexes enhance stability, bioavailability, and anticancer properties, exhibiting potent cytotoxicity through mechanisms like ROS generation, DNA intercalation, and apoptosis induction. This review highlights the latest progress (2022-2024) in the field, emphasizing the structural modifications, and mechanistic insights that have propelled pyridine-metal complexes as potent anticancer agents. Special attention is given to the role of metal complexation in enhancing the anticancer potency of pyridine derivatives, with examples of preclinical studies showing their efficacy against various cancer types. The findings emphasize the potential of pyridine-metal complexes as a transformative approach in oncology, bridging the gap between innovative chemical design and impactful therapeutic applications.

Keywords: Heterocyclic, pyridine, pharmacological, anticancer therapy, metal complexes, bioavailability.

Next »
Graphical Abstract

[1]
Chu, J.J.; Mehrzad, R. The biology of cancer, link between obes. Cancer, 2023, 35-45.
[http://dx.doi.org/10.1016/B978-0-323-90965-5.00012-X]
[2]
Sarkar, S.; Horn, G.; Moulton, K.; Oza, A.; Byler, S.; Kokolus, S.; Longacre, M. Cancer development, progression, and therapy: An epigenetic overview. Int. J. Mol. Sci., 2013, 14, 21087-21113.
[http://dx.doi.org/10.3390/ijms141021087]
[3]
Siegel, R.L.; Giaquinto, A.N.; Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin., 2024, 74(1), 12-49.
[http://dx.doi.org/10.3322/caac.21820]
[4]
Alharbi, A.H.; Khan, S. Antimicrobial, antioxidant, cell imaging and sensing applications of fluorescein derivatives: A review. Anal. Biochem., 2024, 688, 115479.
[http://dx.doi.org/10.1016/j.ab.2024.115479] [PMID: 38342200]
[5]
Mohammad Abu-Taweel, G.; Ibrahim, M.M.; Khan, S.; Al-Saidi, H.M.; Alshamrani, M.; Alhumaydhi, F.A.; Alharthi, S.S. Medicinal importance and chemosensing applications of pyridine derivatives: A review. Crit. Rev. Anal. Chem., 2022, 52, 1-18.
[http://dx.doi.org/10.1080/10408347.2022.2089839] [PMID: 35724248]
[6]
Khan, S.; Alhumaydhi, F.A.; Ibrahim, M.M.; Alqahtani, A.; Alshamrani, M.; Alruwaili, A.S.; Hassanian, A.A.; Khan, S. Recent advances and therapeutic journey of Schiff base complexes with selected metals (Pt, Pd, Ag, Au) as potent anticancer agents: A review. Anticancer. Agents Med. Chem., 2022, 22(18), 3086-3096.
[http://dx.doi.org/10.2174/1871520622666220511125600] [PMID: 35546764]
[7]
Alrooqi, M.; Khan, S.; Alhumaydhi, F.A.; Asiri, S.A.; Alshamrani, M.; Mashraqi, M.M.; Alzamami, A.; Alshahrani, A.M.; Aldahish, A.A. A therapeutic journey of pyridine-based heterocyclic compounds as potent anticancer agents: A review (from 2017 to 2021). Anticancer. Agents Med. Chem., 2022, 22(15), 2775-2787.
[http://dx.doi.org/10.2174/1871520622666220324102849] [PMID: 35331100]
[8]
Law, C.S.W.; Yeong, K.Y. Benzimidazoles in drug discovery: A patent review. ChemMedChem, 2021, 16(12), 1861-1877.
[http://dx.doi.org/10.1002/cmdc.202100004] [PMID: 33646618]
[9]
DOĞAN-S, A.; Özdemir, S.; Yalçin, M.S.; Sari, H.; Nural, Y. Naphthoquinone–thiazole hybrids bearing adamantane: Synthesis, antimicrobial, DNA cleavage, antioxidant activity, acid dissociation constant, and drug-likeness. J. Res. Pharm., 2021, 25(3), 292-304.
[http://dx.doi.org/10.29228/jrp.20]
[10]
Nural, Y.; Gemili, M.; Ulger, M.; Sari, H. Synthesis, antimicrobial activity and acid dissociation constants of methyl 5,5-diphenyl-1-(thiazol-2-yl)pyrrolidine-2-carboxylate derivatives. Bioorg. Med. Chem. Lett., 2018, 28(5), 942-946.
[http://dx.doi.org/10.1016/j.bmcl.2018.01.045]
[11]
Gemili, M.; Nural, Y.; Keleş, E.; Aydıner, B.; Seferoğlu, N.; Ülger, M.; Şahin, E.; Erat, S.; Seferoğlu, Z. Novel highly functionalized 1,4-naphthoquinone 2-iminothiazole hybrids: Synthesis, photophysical properties, crystal structure, DFT studies, and anti(myco)bacterial/antifungal activity. J. Mol. Struct., 2019, 1196, 536-546.
[http://dx.doi.org/10.1016/j.molstruc.2019.06.087]
[12]
Huo, H.; Li, G.; Shi, B.; Li, J. Recent advances on synthesis and biological activities of C-17 aza-heterocycle derived steroids. Bioorg. Med. Chem., 2022, 69, 116882.
[http://dx.doi.org/10.1016/j.bmc.2022.116882] [PMID: 35749841]
[13]
Küçükgüzel, Ş.G.; Çıkla-Süzgün, P. Recent advances bioactive 1,2,4-triazole-3-thiones. Eur. J. Med. Chem., 2015, 97, 830-870.
[http://dx.doi.org/10.1016/j.ejmech.2014.11.033] [PMID: 25563511]
[14]
Sharma, P.C.; Sinhmar, A.; Sharma, A.; Rajak, H.; Pathak, D.P. Medicinal significance of benzothiazole scaffold: An insight view. J. Enzyme Inhib. Med. Chem., 2013, 28(2), 240-266.
[http://dx.doi.org/10.3109/14756366.2012.720572] [PMID: 23030043]
[15]
Tambat, N.; Mulani, S.K.; Ahmad, A.; Shaikh, S.B.; Ahmed, K. Pyrazine derivatives—versatile scaffold. Russ. J. Bioorg. Chem., 2022, 48, 865-895.
[http://dx.doi.org/10.1134/S1068162022050259]
[16]
Hou, W.; Dai, W.; Huang, H.; Liu, S.L.; Liu, J.; Huang, L.J.; Huang, X.H.; Zeng, J.L.; Gan, Z.W.; Zhang, Z.Y.; Lan, J.X. Pharmacological activity and mechanism of pyrazines. Eur. J. Med. Chem., 2023, 258, 115544.
[http://dx.doi.org/10.1016/j.ejmech.2023.115544] [PMID: 37300915]
[17]
Bhilare, N.V.; Auti, P.B.; Marulkar, V.S.; Pise, V.J. Diverse thiophenes as scaffolds in anti-cancer drug development: A concise review. Mini Rev. Med. Chem., 2021, 21(2), 217-232.
[http://dx.doi.org/10.2174/18755607MTExyOTkg0] [PMID: 33267760]
[18]
Alizadeh, S.R.; Ebrahimzadeh, M.A. Antiviral activities of pyridine fused and pyridine containing heterocycles, a review (from 2000 to 2020). Mini Rev. Med. Chem., 2021, 21(17), 2584-2611.
[http://dx.doi.org/10.2174/18755607MTEzvNjcu0] [PMID: 33573543]
[19]
Tahir, T.; Ashfaq, M.; Saleem, M.; Rafiq, M.; Shahzad, M.I.; Kotwica-Mojzych, K.; Mojzych, M. Pyridine scaffolds, phenols and derivatives of azo moiety: Current therapeutic perspectives. Molecules, 2021, 26(16), 4872.
[http://dx.doi.org/10.3390/molecules26164872] [PMID: 34443460]
[20]
Allaka, T.R.; Katari, N.K. Synthesis of pyridine derivatives for diverse biological activity profiles: A review. In: Recent Developments in the Synthesis and Applications of Pyridines; Elsevier, 2023; pp. 605-625.
[http://dx.doi.org/10.1016/B978-0-323-91221-1.00005-1]
[21]
Chiacchio, M.A.; Iannazzo, D.; Romeo, R.; Giofrè, S.V.; Legnani, L. Pyridine and pyrimidine derivatives as privileged scaffolds in biologically active agents. Curr. Med. Chem., 2020, 26(40), 7166-7195.
[http://dx.doi.org/10.2174/0929867325666180904125400] [PMID: 30182842]
[22]
Prachayasittikul, S.; Pingaew, R.; Worachartcheewan, A.; Sinthupoom, N.; Prachayasittikul, V.; Ruchirawat, S.; Prachayasittikul, V. Roles of pyridine and pyrimidine derivatives as privileged scaffolds in anticancer agents. Mini Rev. Med. Chem., 2017, 17(10), 869-901.
[http://dx.doi.org/10.2174/1389557516666160923125801] [PMID: 27670581]
[23]
Manaithiya, A.; Alam, O.; Sharma, V.; Naim, M.J.; Mittal, S.; Azam, F.; Husain, A.; Sheikh, A.A.; Imran, M.; Khan, I.A. Current status of novel pyridine fused derivatives as anticancer agents: An insight into future perspectives and structure activity relationship (SAR). Curr. Top. Med. Chem., 2021, 21(25), 2292-2349.
[http://dx.doi.org/10.2174/1568026621666210916171015] [PMID: 34530713]
[24]
Albratty, M.; Alhazmi, H.A. Novel pyridine and pyrimidine derivatives as promising anticancer agents: A review. Arab. J. Chem., 2022, 15(6), 103846.
[http://dx.doi.org/10.1016/j.arabjc.2022.103846]
[25]
Abadi, A.H.; Ibrahim, T.M.; Abouzid, K.M.; Lehmann, J.; Tinsley, H.N.; Gary, B.D.; Piazza, G.A. Design, synthesis and biological evaluation of novel pyridine derivatives as anticancer agents and phosphodiesterase 3 inhibitors. Bioorg. Med. Chem., 2009, 17(16), 5974-5982.
[http://dx.doi.org/10.1016/j.bmc.2009.06.063] [PMID: 19628397]
[26]
Zhang, Y-B.; Liu, W.; Yang, Y.S.; Wang, X.L.; Zhu, H.L.; Bai, L.F.; Qiu, X.Y. Synthesis, molecular modeling, and biological evaluation of 1,2,4-triazole derivatives containing pyridine as potential anti-tumor agents. Med. Chem. Res., 2013, 22(7), 3193-3203.
[http://dx.doi.org/10.1007/s00044-012-0306-5]
[27]
Smułek, W.; Kaczorek, E. Factors influencing the bioavailability of organic molecules to bacterial cells—a mini-review. Mol., 2022, 27, 6579.
[http://dx.doi.org/10.3390/molecules27196579]
[28]
Szabó, R.; Rácz, C.P.; Dulf, F.V. Bioavailability improvement strategies for icariin and its derivatives: A review. Int. J. Mol. Sci., 2022, 23, 7519.
[http://dx.doi.org/10.3390/ijms23147519]
[29]
Sabet, S.; Rashidinejad, A.; Melton, L.D.; McGillivray, D.J. Recent advances to improve curcumin oral bioavailability. Trends Food Sci. Technol., 2021, 110, 253-266.
[http://dx.doi.org/10.1016/j.tifs.2021.02.006]
[30]
Ramesh, A.; Walker, S.A.; Hood, D.B.; Guillén, M.D.; Schneider, K.; Weyand, E.H. Bioavailability and risk assessment of orally ingested polycyclic aromatic hydrocarbons. Int. J. Toxicol., 2004, 23(5), 301-333.
[http://dx.doi.org/10.1080/10915810490517063] [PMID: 15513831]
[31]
Wu, K.; Kwon, S.H.; Zhou, X.; Fuller, C.; Wang, X.; Vadgama, J.; Wu, Y. Overcoming challenges in small-molecule drug bioavailability: A review of key factors and approaches. Int. J. Mol. Sci., 2024, 25, 13121.
[http://dx.doi.org/10.3390/ijms252313121]
[32]
Alshamrani, M. Recent advances and therapeutic journey of pyridine-based Cu(II) complexes as potent anticancer agents: A review (2015–2022). J. Coord. Chem., 2023, 76(1), 1-19.
[http://dx.doi.org/10.1080/00958972.2022.2164190]
[33]
BenGuzzi, S.A.; Abubakr, A.S.; Hassan, S.S. Structural and biological studies of mononuclear metal (II) complexes containing hetero ligand based on 3-acetylpyridine thiosemicarbazone. Appl. Organomet. Chem., 2023, 37, e7203.
[http://dx.doi.org/10.1002/aoc.7203]
[34]
Huang, Q.W.; Liu, S.G.; Li, G.B.; Wang, S.X.; Su, W.Y.; Liang, D.M.; Mao, S.Q. Crystal structure and antitumor activities of the dichloride 2,6-bis(1-phenylbenzimidazol-2-yl)pyridine copper(II) complex. J. Struct. Chem., 2015, 56(3), 458-462.
[http://dx.doi.org/10.1134/S0022476615030087]
[35]
Liu, Z.; Romero-Canelón, I.; Habtemariam, A.; Clarkson, G.J.; Sadler, P.J. Potent half-sandwich iridium(III) anticancer complexes containing C^N-chelated and pyridine ligands. Organometallics, 2014, 33(19), 5324-5333.
[http://dx.doi.org/10.1021/om500644f] [PMID: 25328266]
[36]
Halcrow, M.A. The synthesis and coordination chemistry of 2,6-bis(pyrazolyl)pyridines and related ligands — Versatile terpyridine analogues. Coord. Chem. Rev., 2005, 249(24), 2880-2908.
[http://dx.doi.org/10.1016/j.ccr.2005.03.010]
[37]
McPherson, J.N.; Das, B.; Colbran, S.B. Tridentate pyridine–pyrrolide chelate ligands: An under-appreciated ligand set with an immensely promising coordination chemistry. Coord. Chem. Rev., 2018, 375, 285-332.
[http://dx.doi.org/10.1016/j.ccr.2018.01.012]
[38]
Ilmi, R.; Juma Al-busaidi, I.; Haque, A.; Khan, M.S. Recent progress in coordination chemistry, photo-physical properties, and applications of pyridine-based Cu(I) complexes. J. Coord. Chem., 2018, 71(19), 3045-3076.
[http://dx.doi.org/10.1080/00958972.2018.1509070]
[39]
Martinez-Bulit, P.; Garza-Ortíz, A.; Mijangos, E.; Barrón-Sosa, L.; Sánchez-Bartéz, F.; Gracia-Mora, I.; Flores-Parra, A.; Contreras, R.; Reedijk, J.; Barba-Behrens, N. 2,6-Bis(2,6-diethylphenyliminomethyl)pyridine coordination compounds with cobalt(II), nickel(II), copper(II), and zinc(II): Synthesis, spectroscopic characterization, X-ray study and in vitro cytotoxicity. J. Inorg. Biochem., 2015, 142, 1-7.
[http://dx.doi.org/10.1016/j.jinorgbio.2014.09.007] [PMID: 25282405]
[40]
González-Bártulos, M.; Aceves-Luquero, C.; Qualai, J.; Cussó, O.; Martínez, M.A.; Fernández de Mattos, S.; Menéndez, J.A.; Villalonga, P.; Costas, M.; Ribas, X.; Massaguer, A. Pro-oxidant activity of amine-pyridine-based iron complexes efficiently kills cancer and cancer stem-like cells. PLoS One, 2015, 10(9), e0137800.
[http://dx.doi.org/10.1371/journal.pone.0137800] [PMID: 26368127]
[41]
Tyagi, S.; Mishra, R.; Mazumder, R.; Mazumder, A. Current market potential and prospects of copper-based pyridine derivatives: A review. Curr. Mol. Med., 2024, 24(9), 1111-1123.
[http://dx.doi.org/10.2174/1566524023666230726160056] [PMID: 37496249]
[42]
Jiang, M.; Su, X.; Zhong, X.; Lan, Y.; Yang, F.; Qin, Y.; Jiang, C. Recent development of Schiff-base metal complexes as therapeutic agents for lung cancer. J. Mol. Struct., 2024, 1318, 139403.
[http://dx.doi.org/10.1016/j.molstruc.2024.139403]
[43]
Tyagi, M.; Dubey, M. A fight against cancer with advancement of Schiff base metal complexes: Future prospects. Oral Oncology Reports, 2025, 13, 100692.
[http://dx.doi.org/10.1016/j.oor.2024.100692]
[44]
Khan, H.Y.; Ansari, M.F.; Tabassum, S.; Arjmand, F. A review on the recent advances of interaction studies of anticancer metal-based drugs with therapeutic targets, DNA and RNAs. Drug Discov. Today, 2024, 29(7), 104055.
[http://dx.doi.org/10.1016/j.drudis.2024.104055] [PMID: 38852835]
[45]
Abdolmaleki, S.; Aliabadi, A.; Khaksar, S. Riding the metal wave: A review of the latest developments in metal-based anticancer agents. Coord. Chem. Rev., 2024, 501, 215579.
[http://dx.doi.org/10.1016/j.ccr.2023.215579]
[46]
Hangan, A.C.; Oprean, L.S.; Dican, L.; Procopciuc, L.M.; Sevastre, B.; Lucaciu, R.L. Metal-based drug–DNA interactions and analytical determination methods. Molecules, 2024, 29(18), 4361.
[http://dx.doi.org/10.3390/molecules29184361] [PMID: 39339356]
[47]
Dasmahapatra, U.; Maiti, B.; Alam, M.M.; Chanda, K. Anti-cancer property and DNA binding interaction of first row transition metal complexes: A decade update. Eur. J. Med. Chem., 2024, 275, 116603.
[http://dx.doi.org/10.1016/j.ejmech.2024.116603] [PMID: 38936150]
[48]
Peña, Q.; Sciortino, G.; Maréchal, J.D.; Bertaina, S.; Simaan, A.J.; Lorenzo, J.; Capdevila, M.; Bayón, P.; Iranzo, O.; Palacios, Ò.; Copper, N. II Copper(II) N, N, O -chelating complexes as potential anticancer agents. Inorg. Chem., 2021, 60(5), 2939-2952.
[http://dx.doi.org/10.1021/acs.inorgchem.0c02932] [PMID: 33596377]
[49]
Abu-Dief, A.M.; Mohamed, I.M.A. A review on versatile applications of transition metal complexes incorporating Schiff bases. Beni. Suef Univ. J. Basic Appl. Sci., 2015, 4(2), 119-133.
[http://dx.doi.org/10.1016/j.bjbas.2015.05.004] [PMID: 32289037]
[50]
Santini, C.; Pellei, M.; Gandin, V.; Porchia, M.; Tisato, F.; Marzano, C. Advances in copper complexes as anticancer agents. Chem. Rev., 2014, 114(1), 815-862.
[http://dx.doi.org/10.1021/cr400135x] [PMID: 24102434]
[51]
Singh, N.K.; Kumbhar, A.A.; Pokharel, Y.R.; Yadav, P.N. Anticancer potency of copper(II) complexes of thiosemicarbazones. J. Inorg. Biochem., 2020, 210, 111134.
[http://dx.doi.org/10.1016/j.jinorgbio.2020.111134] [PMID: 32673842]
[52]
Rubbiani, R.; Zehnder, T.N.; Mari, C.; Blacque, O.; Venkatesan, K.; Gasser, G. Anticancer profile of a series of gold(III) (2-phenyl)pyridine complexes. ChemMedChem, 2014, 9(12), 2781-2790.
[http://dx.doi.org/10.1002/cmdc.201402446] [PMID: 25377650]
[53]
Kutlu, E.; Emen, F.M.; Kismali, G.; Kınaytürk, N.K.; Kılıç, D.; Karacolak, A.I.; Demirdogen, R.E. Pyridine derivative platinum complexes: Synthesis, molecular structure, DFT and initial anticancer activity studies. J. Mol. Struct., 2021, 1234, 130191.
[http://dx.doi.org/10.1016/j.molstruc.2021.130191]
[54]
Choroba, K.; Machura, B.; Kula, S.; Raposo, L.R.; Fernandes, A.R.; Kruszynski, R.; Erfurt, K.; Shul’pina, L.S.; Kozlov, Y.N.; Shul’pin, G.B. Copper(II) complexes with 2,2′:6′,2′′-terpyridine, 2,6-di(thiazol-2-yl)pyridine and 2,6-di(pyrazin-2-yl)pyridine substituted with quinolines. Synthesis, structure, antiproliferative activity, and catalytic activity in the oxidation of alkanes and alcohols with peroxides. Dalton Trans., 2019, 48(33), 12656-12673.
[http://dx.doi.org/10.1039/C9DT01922G] [PMID: 31384866]
[55]
Abdolmaleki, S.; Ghadermazi, M.; Aliabadi, A. Study on electrochemical behavior and in vitro anticancer effect of Co(II) and Zn(II) complexes containing pyridine-2,6-dicarboxylate. Inorg. Chim. Acta, 2021, 527, 120549.
[http://dx.doi.org/10.1016/j.ica.2021.120549]
[56]
Fernandes, A.S.; Costa, J.; Gaspar, J.; Rueff, J.; Cabral, M.F.; Cipriano, M.; Castro, M.; Oliveira, N.G. Development of pyridine-containing macrocyclic copper(II) complexes: Potential role in the redox modulation of oxaliplatin toxicity in human breast cells. Free Radic. Res., 2012, 46(9), 1157-1166.
[http://dx.doi.org/10.3109/10715762.2012.695869] [PMID: 22612279]
[57]
Abdolmaleki, S.; Ghadermazi, M.; Aliabadi, A. Novel Tl(III) complexes containing pyridine-2,6-dicarboxylate derivatives with selective anticancer activity through inducing mitochondria-mediated apoptosis in A375 cells. Sci. Rep., 2021, 11(1), 15699.
[http://dx.doi.org/10.1038/s41598-021-95278-y]
[58]
Ghasemi, L.; Behzad, M.; Khaleghian, A.; Abbasi, A.; Abedi, A. Synthesis and characterization of two new mixed‐ligand Cu(II) complexes of a tridentate NN’O type Schiff base ligand and N‐donor heterocyclic co‐ligands: In vitro anticancer assay, DNA/human leukemia/COVID‐19 molecular docking studies, and pharmacophore modeling. Appl. Organomet. Chem., 2022, 36(5), e6639.
[http://dx.doi.org/10.1002/aoc.6639] [PMID: 35538931]
[59]
Qu, J.J.; Bai, P.; Liu, W.N.; Liu, Z.L.; Gong, J.F.; Wang, J.X.; Zhu, X.; Song, B.; Hao, X.Q. New NNN pincer copper complexes as potential anti-prostate cancer agents. Eur. J. Med. Chem., 2022, 244, 114859.
[http://dx.doi.org/10.1016/j.ejmech.2022.114859] [PMID: 36308778]
[60]
Moradi, H.S.; Momenzadeh, E.; Asar, M.; Iranpour, S.; Bahrami, A.R.; Bazargan, M.; Hassanzadeh, H.; Matin, M.M.; Mirzaei, M. Bioactivity studies of two copper complexes based on pyridinedicarboxylic acid N-oxide and 2,2′-bipyridine. J. Mol. Struct., 2022, 1249, 131584.
[http://dx.doi.org/10.1016/j.molstruc.2021.131584]
[61]
Malik, M.; Świtlicka, A.; Bieńko, A.; Komarnicka, U.K.; Bieńko, D.C.; Kozieł, S.; Kyzioł, A.; Mazur, T.; Machura, B. Copper(II) complexes with 2-ethylpyridine and related hydroxyl pyridine derivatives: Structural, spectroscopic, magnetic and anticancer in vitro studies. RSC Advances, 2022, 12(42), 27648-27665.
[http://dx.doi.org/10.1039/D2RA05133H] [PMID: 36276031]
[62]
Adhikari, H.S.; Garai, A.; Manandhar, K.D.; Yadav, P.N. Pyridine-based NNS tridentate chitosan thiosemicarbazones and their Copper(II) complexes: Synthesis, characterization, and anticancer activity. ACS Omega, 2022, 7(35), 30978-30988.
[http://dx.doi.org/10.1021/acsomega.2c02966] [PMID: 36092560]
[63]
Wu, Y.; Hou, L.; Lan, J.; Yang, F.; Huang, G.; Liu, W.; Gou, Y. Mixed-ligand copper(II) hydrazone complexes: Synthesis, structure, and anti-lung cancer properties. J. Mol. Struct., 2023, 1279, 134986.
[http://dx.doi.org/10.1016/j.molstruc.2023.134986]
[64]
Chen, Y.M.; Liu, Y.C.; Wang, J.Q.; Ou, G.C.; Wang, X.F.; Gao, S.Q.; Du, K.J.; Lin, Y.W. Functional copper complexes with benzofurans tridentate ligand: Synthesis, crystal structure, DNA binding and anticancer studies. J. Inorg. Biochem., 2023, 247, 112330.
[http://dx.doi.org/10.1016/j.jinorgbio.2023.112330] [PMID: 37478782]
[65]
Lu, W.; Tang, J.; Gu, Z.; Sun, L.; Wei, H.; Wang, Y.; Yang, S.; Chi, X.; Xu, L. Crystal structure, in vitro cytotoxicity, DNA binding and DFT calculations of new copper (II) complexes with coumarin-amide ligand. J. Inorg. Biochem., 2023, 238, 112030.
[http://dx.doi.org/10.1016/j.jinorgbio.2022.112030] [PMID: 36327496]
[66]
Topal, T. Synthesis and characterization of zinc(II) complexes with new pyridine-based ligands: Crystal structure, Hirshfeld surface analysis, and molecular docking study of lung cancer cell. J. Coord. Chem., 2020, 73(23), 3203-3222.
[http://dx.doi.org/10.1080/00958972.2020.1853710]
[67]
Dam, J.; Ismail, Z.; Kurebwa, T.; Gangat, N.; Harmse, L.; Marques, H.M.; Lemmerer, A.; Bode, M.L.; de Koning, C.B. Synthesis of copper and zinc 2-(pyridin-2-yl)imidazo[1,2-a]pyridine complexes and their potential anticancer activity. Eur. J. Med. Chem., 2017, 126, 353-368.
[http://dx.doi.org/10.1016/j.ejmech.2016.10.041] [PMID: 27907874]
[68]
Stanojkovic, T.P.; Kovala-Demertzi, D.; Primikyri, A.; Garcia-Santos, I.; Castineiras, A.; Juranic, Z.; Demertzis, M.A. Zinc(II) complexes of 2-acetyl pyridine 1-(4-fluorophenyl)-piperazinyl thiosemicarbazone: Synthesis, spectroscopic study and crystal structures – Potential anticancer drugs. J. Inorg. Biochem., 2010, 104(4), 467-476.
[http://dx.doi.org/10.1016/j.jinorgbio.2009.12.021] [PMID: 20102782]
[69]
Gao, E.; Sun, T.; Liu, S.; Ma, S.; Wen, Z.; Wang, Y.; Zhu, M.; Wang, L.; Gao, X.; Guan, F.; Guo, M.J.; Liu, F.C. Synthesis, characterization, interaction with DNA and cytotoxicity in vitro of novel pyridine complexes with Zn(II). Eur. J. Med. Chem., 2010, 45(10), 4531-4538.
[http://dx.doi.org/10.1016/j.ejmech.2010.07.013] [PMID: 20692739]
[70]
Araškov, J.B.; Višnjevac, A.; Popović, J.; Blagojević, V.; Fernandes, H.S.; Sousa, S.F.; Novaković, I.; Padrón, J.M.; Holló, B.B.; Monge, M.; Rodríguez-Castillo, M.; López-de-Luzuriaga, J.M.; Filipović, N.R.; Todorović, T.R. Zn(II) complexes with thiazolyl–hydrazones: Structure, intermolecular interactions, photophysical properties, computational study and anticancer activity. CrystEngComm, 2022, 24(29), 5194-5214.
[http://dx.doi.org/10.1039/D2CE00443G]
[71]
Chang, Q.; Xie, Y.; Lu, X.; Zong, Z.; Zhang, E.; Cao, S.; Liang, L. In vitro and in vivo antiproliferative activity on lung cancer of two acylhydrazone based zinc(II) complexes. Bioorg. Chem., 2024, 147, 107422.
[http://dx.doi.org/10.1016/j.bioorg.2024.107422] [PMID: 38705106]
[72]
Wang, Z.F.; Zhou, X.F.; Wei, Q.C.; Qin, Q.P.; Li, J.X.; Tan, M.X.; Zhang, S.H. Novel bifluorescent Zn(II)–cryptolepine–cyclen complexes trigger apoptosis induced by nuclear and mitochondrial DNA damage in cisplatin-resistant lung tumor cells. Eur. J. Med. Chem., 2022, 238, 114418.
[http://dx.doi.org/10.1016/j.ejmech.2022.114418] [PMID: 35525079]
[73]
Adhikari, S.; Nath, S.; Kansız, S.; Balidya, N.; Paul, A.K.; Dege, N.; Sahin, O.; Mahmoudi, G.; Verma, A.K.; Safin, D.A. Zinc(II) coordination compound with N′-(pyridin-2-ylmethylene)nicotinohydrazide: Synthesis, crystal structure, computational and cytotoxicity studies. J. Inorg. Biochem., 2024, 257, 112598.
[http://dx.doi.org/10.1016/j.jinorgbio.2024.112598] [PMID: 38763101]
[74]
Hassan, M.; El-Faham, A.; Barakat, A.; Haukka, M.; Tatikonda, R.; Abu-Youssef, M.A.M.; Soliman, S.M.; Yousri, A. Synthesis, X-ray structure, cytotoxic, and anti-microbial activities of Zn(II) complexes with a hydrazono s-triazine bearing pyridyl arm. Inorganics, 2024, 12(7), 176.
[http://dx.doi.org/10.3390/inorganics12070176]
[75]
Chen, D.Y.; Chen, C.L.; Li, M.X.; Niu, J.Y.; Zhu, X.F.; Guo, H.M. Synthesis, crystal structure, and biological activity of a nickel(II) complex of 2-acetylpyridine N(4)-methylthiosemicarbazone. J. Coord. Chem., 2010, 63(9), 1546-1554.
[http://dx.doi.org/10.1080/00958972.2010.484490]
[76]
Choo, K.B.; Lee, S.M.; Lee, W.L.; Cheow, Y.L. Synthesis, characterization, in vitro antimicrobial and anticancer studies of new platinum N-heterocyclic carbene (NHC) complexes and unexpected nickel complexes. J. Organomet. Chem., 2019, 898, 120868.
[http://dx.doi.org/10.1016/j.jorganchem.2019.07.019]
[77]
Yang, J.M.; Zhu, Y.H.; Chen, S.; Lu, X.; Wu, Y.M.; Ma, F.E.; Li, L.P.; Yang, Y.; Shi, Z.H.; Huang, K.Y.; Hong, X.; Jiang, P.; Peng, Y. A β-carboline derivative-based nickel(II) complex as a potential antitumor agent: Synthesis, characterization, and cytotoxicity. MedChemComm, 2018, 9(1), 100-107.
[http://dx.doi.org/10.1039/C7MD00428A] [PMID: 30108903]
[78]
Bhattacharjee, T.; Adhikari, S.; Sheikh, A.H.; Mahmoudi, G.; Mlowe, S.; Akerman, M.P.; Choudhury, N.A.; Chakraborty, S.; Butcher, R.J.; Kennedy, A.R.; Demir, B.S.; Örs, A.; Saygideger, Y. Syntheses, crystal structures, theoretical studies, and anticancer properties of an unsymmetrical schiff base ligand N-2-(6-methylpyridyl)-2-hydroxy-1-naphthaldimine and its Ni(II) complex. J. Mol. Struct., 2022, 1269, 133717.
[http://dx.doi.org/10.1016/j.molstruc.2022.133717]
[79]
Keypour, H.; Tafazzoli, A.; Farida, H.M.S.; Abdollahi-Moghadam, M.; William, G.R. Synthesis, investigation of biological activities and theoretical studies of a novel hexaaza Schiff base ligand and its Ni(II) complex: X-ray crystal structure of the Ni(II) complex. Inorg. Chem. Commun., 2023, 155, 110981.
[http://dx.doi.org/10.1016/j.inoche.2023.110981]
[80]
Panicker, R.R.; Sivaramakrishna, A. Studies on synthesis and influence of sterically driven Ni(II)-terpyridine (NNN) complexes on BSA/DNA binding and anticancer activity. J. Inorg. Biochem., 2024, 257, 112553.
[http://dx.doi.org/10.1016/j.jinorgbio.2024.112553] [PMID: 38759263]
[81]
Huang, X.; Wang, B.; Sun, D.; Chen, M.; Xue, X.; Liu, H.; Zhou, Y.; Ma, Z. Synthesis of substituted terpyridine nickel nitrate complexes and their inhibitory selectivity against cancer cell lines. J. Inorg. Biochem., 2024, 256, 112554.
[http://dx.doi.org/10.1016/j.jinorgbio.2024.112554] [PMID: 38613885]
[82]
Manikandan, R.; Viswanathamurthi, P.; Velmurugan, K.; Nandhakumar, R.; Hashimoto, T.; Endo, A. Synthesis, characterization and crystal structure of cobalt(III) complexes containing 2-acetylpyridine thiosemicarbazones: DNA/protein interaction, radical scavenging and cytotoxic activities. J. Photochem. Photobiol. B, 2014, 130, 205-216.
[http://dx.doi.org/10.1016/j.jphotobiol.2013.11.008] [PMID: 24342132]
[83]
Qin, Q.P.; Qin, J.L.; Meng, T.; Lin, W.H.; Zhang, C.H.; Wei, Z.Z.; Chen, J.N.; Liu, Y.C.; Liang, H.; Chen, Z.F. High in vivo antitumor activity of cobalt oxoisoaporphine complexes by targeting G-quadruplex DNA, telomerase and disrupting mitochondrial functions. Eur. J. Med. Chem., 2016, 124, 380-392.
[http://dx.doi.org/10.1016/j.ejmech.2016.08.063] [PMID: 27597414]
[84]
Karumban, K.S.; Muley, A.; Raut, R.; Gupta, P.; Giri, B.; Kumbhakar, S.; Misra, A.; Maji, S. Mononuclear Co(II) polypyridyl complexes: Synthesis, molecular structure, DNA binding/cleavage, radical scavenging, docking studies and anticancer activities. Dalton Trans., 2022, 51(18), 7084-7099.
[http://dx.doi.org/10.1039/D1DT04144D] [PMID: 35357373]
[85]
Karumban, K.S.; Raut, R.; Gupta, P.; Muley, A.; Giri, B.; Kumbhakar, S.; Misra, A.; Maji, S. Mononuclear cobalt(II) complexes with polypyridyl ligands: Synthesis, characterization, DNA interactions and in vitro cytotoxicity towards human cancer cells. J. Inorg. Biochem., 2022, 233, 111866.
[http://dx.doi.org/10.1016/j.jinorgbio.2022.111866] [PMID: 35636303]
[86]
Subhash, J.; Jyoti.; Chaudhary, A. Synthesis, spectroscopic characterization, in vitro cytotoxic, antimicrobial and antioxidant studies of Co(II) complexes bearing pyridine-based macrocyclic ligands with density function theory (DFT) and molecular docking investigations. Res. Chem. Intermed., 2023, 49(11), 4729-4758.
[http://dx.doi.org/10.1007/s11164-023-05096-2]
[87]
Nnabuike, G.G.; Salunke-Gawali, S.; Patil, A.S.; Butcher, R.J.; Obaleye, J.A.; Ashtekar, H.; Prakash, B. Cobalt(II) complexes containing mefenamic acid with imidazole and pyridine based auxiliary ligands: Synthesis, structural investigation and cytotoxic evaluation. J. Mol. Struct., 2023, 1285, 135519.
[http://dx.doi.org/10.1016/j.molstruc.2023.135519]
[88]
Kovala-Demertzi, D.; Demertzis, M.A.; Miller, J.R.; Papadopoulou, C.; Dodorou, C.; Filousis, G. Platinum(II) complexes with 2-acetyl pyridine thiosemicarbazone synthesis, crystal structure, spectral properties, antimicrobial and antitumour activity. J. Inorg. Biochem., 2001, 86(2-3), 555-563.
[http://dx.doi.org/10.1016/S0162-0134(01)00224-0] [PMID: 11566327]
[89]
Segapelo, T.V.; Guzei, I.A.; Spencer, L.C.; Zyl, W.E.V.; Darkwa, J. (Pyrazolylmethyl)pyridine platinum(II) and gold(III) complexes: Synthesis, structures and evaluation as anticancer agents. Inorg. Chim. Acta, 2009, 362(9), 3314-3324.
[http://dx.doi.org/10.1016/j.ica.2009.02.046]
[90]
Kovala-Demertzi, D.; Yadav, P.N.; Demertzis, M.A.; Coluccia, M. Synthesis, crystal structure, spectral properties and cytotoxic activity of platinum(II) complexes of 2-acetyl pyridine and pyridine-2-carbaldehyde N(4)-ethyl-thiosemicarbazones. J. Inorg. Biochem., 2000, 78(4), 347-354.
[http://dx.doi.org/10.1016/S0162-0134(00)00063-5] [PMID: 10857916]
[91]
Masaryk, L.; Zoufalý, P.; Słoczyńska, K.; Zahradniková, E.; Milde, D.; Koczurkiewicz-Adamczyk, P.; Štarha, P. New Pt(II) diiodido complexes containing bidentate 1,3,4-thiadiazole-based ligands: Synthesis, characterization, cytotoxicity. Inorg. Chim. Acta, 2022, 536, 120891.
[http://dx.doi.org/10.1016/j.ica.2022.120891]
[92]
Hosseini-Hashemi, Z.; Eslami, M.M.; Mirzaei, M.; Notash, B. Biological activity of two anticancer pt complexes with a cyclohexylglycine ligand against a colon cancer cell line: Theoretical and experimental study. ACS Omega, 2022, 7(44), 39794-39811.
[http://dx.doi.org/10.1021/acsomega.2c03776] [PMID: 36385884]
[93]
McGhie, B.S.; Sakoff, J.; Gilbert, J.; Gordon, C.P.; Aldrich-Wright, J.R. Synthesis and characterisation of Platinum(II) Diaminocyclohexane complexes with pyridine derivatives as anticancer agents. Int. J. Mol. Sci., 2023, 24(24), 17150.
[http://dx.doi.org/10.3390/ijms242417150] [PMID: 38138979]
[94]
Bhaduri, R.; Moi, S.C. Bio-physical and theoretical investigations on Pt(II)-pyridine based complexes with relevant bio-molecules for the development of potent anticancer drug candidates. J. Mol. Struct., 2024, 1309, 138261.
[http://dx.doi.org/10.1016/j.molstruc.2024.138261]
[95]
Kovala-Demertzi, D.; Alexandratos, A.; Papageorgiou, A.; Yadav, P.N.; Dalezis, P.; Demertzis, M.A. Synthesis, characterization, crystal structures, in vitro and in vivo antitumor activity of palladium(II) and zinc(II) complexes with 2-formyl and 2-acetyl pyridine N(4)-1-(2-pyridyl)-piperazinyl thiosemicarbazone. Polyhedron, 2008, 27(13), 2731-2738.
[http://dx.doi.org/10.1016/j.poly.2008.04.009]
[96]
Krogul, A.; Cedrowski, J.; Wiktorska, K.; Ozimiński, W.P.; Skupińska, J.; Litwinienko, G. Crystal structure, electronic properties and cytotoxic activity of palladium chloride complexes with monosubstituted pyridines. Dalton Trans., 2012, 41(2), 658-666.
[http://dx.doi.org/10.1039/C1DT11412C] [PMID: 22068915]
[97]
Zhang, L.Z.; Ding, T.; Chen, C.L.; Li, M.X.; Zhang, D.; Niu, J.Y. Biological activities of pyridine-2-carbaldehyde Schiff bases derived from S-methyl- and S-benzyldithiocarbazate and their zinc(II) and manganese(II) complexes. Crystal Structure of the Manganese(II) complex of pyridine-2-carbaldehyde S-benzyldithiocarbazate. Russ. J. Coord. Chem., 2011, 37(5), 356-361.
[http://dx.doi.org/10.1134/S1070328411040117]
[98]
Tamer, Ö.; Mahmoody, H.; Feyzioğlu, K.F.; Kılınç, O.; Avci, D.; Orun, O.; Dege, N.; Atalay, Y. Synthesis of the first mixed ligand Mn (II) and Cd (II) complexes of 4‐methoxy‐pyridine‐2‐carboxylic acid, molecular docking studies and investigation of their anti‐tumor effects in vitro. Appl. Organomet. Chem., 2020, 34(3), e5416.
[http://dx.doi.org/10.1002/aoc.5416]
[99]
Khalil, T.E.; Soliman, S.M.; Khalil, N.A.; El-Dissouky, A.; Foro, S.; Ali, M.; Barakat, A. Self‐assembly of unexpected [Mn(2‐(1‐hydrazonoethyl)pyridine)Cl2]n 1D coordination polymer: Synthesis, structural elucidation, and biological studies. Appl. Organomet. Chem., 2022, 36(9), e6812.
[http://dx.doi.org/10.1002/aoc.6812]
[100]
Bhaduri, R.; Pan, A.; Kumar, T.S.; Mandal, S.; Bagchi, A.; Biswas, A.; Ch, S.M. In vitro anticancer activity of Pd(II) complexes with pyridine scaffold: Their bioactivity, role in cell cycle arrest, and computational study. J. Mol. Liq., 2022, 367, 120540.
[http://dx.doi.org/10.1016/j.molliq.2022.120540]
[101]
Fathalla, E.M.; Abu-Youssef, M.A.M.; Sharaf, M.M.; El-Faham, A.; Barakat, A.; Badr, A.M.A.; Soliman, S.M.; Slawin, A.M.Z.; Woollins, J.D. Synthesis, characterizations, antitumor and antimicrobial evaluations of novel Mn(II) and Cu(II) complexes with NNN-tridentate s-Triazine-Schiff base ligand. Inorg. Chim. Acta, 2023, 555, 121586.
[http://dx.doi.org/10.1016/j.ica.2023.121586]
[102]
Selvam, P.; De, S.; Paira, P.; Kumar, S.K.A.; Kumar, R.S.; Moorthy, A.; Ghosh, A.; Kuo, Y.C.; Banerjee, S.; Jenifer, S.K. In vitro studies on the selective cytotoxic effect of luminescent Ru(II)- p -cymene complexes of imidazo-pyridine and imidazo quinoline ligands. Dalton Trans., 2022, 51(45), 17263-17276.
[http://dx.doi.org/10.1039/D2DT02237K] [PMID: 36317406]
[103]
Li, J.; Chen, M.; Jiang, J.; Huang, J.; Chen, H.; Pan, L.; Nesterov, D.S.; Ma, Z.; Pombeiro, A.J.L. A new concept of enhancing the anticancer activity of manganese terpyridine complex by oxygen-containing substituent modification. Int. J. Mol. Sci., 2023, 24(4), 3903.
[http://dx.doi.org/10.3390/ijms24043903] [PMID: 36835315]

Rights & Permissions Print Cite
Article Metrics
36
2
Wayfinder Image
© 2026 Bentham Science Publishers | Privacy Policy